Grifols (GRFS)
(Delayed Data from NSDQ)
$8.70 USD
-0.10 (-1.14%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $8.71 +0.01 (0.11%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
GRFS 8.70 -0.10(-1.14%)
Will GRFS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GRFS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GRFS
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
GRFS: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Other News for GRFS
Grifols shareholder group seeks board seat, Bloomberg reports
Grifols Class B stock falls as Brookfield reportedly seeks lower price
Grifols postpones Capital Markets Day until further notice
What's Driving Grifols SA's Surprising 32% Stock Rally?
Brookfield in talks with sovereign funds over Grifols bid: report